Literature DB >> 21302492

[Effects of shexiang baoxin pill on angiogenesis in atherosclerosis plaque and ischemic myocardium].

Wei Shen1, Wei-hu Fan, Hai-ming Shi.   

Abstract

OBJECTIVE: To investigate the effects of Shexiang Baoxin Pill (SBP) in intervening atherosclerosis and myocardial infarction (AS-MI) in experimental animals, and inspect its influences on angiogenesis.
METHODS: Twenty male New-Zealand rabbits were made into AS-MI model, and randomly divided into 2 groups equally. Group A was fed with high-fat diet for control; Group B was fed with high-fat diet but intervened with SBP. The cardiac function and the positive area of plaque were determined. The CD34 positive response intensity at infarcted marginal zone and aorta vessel wall, and the capillary density of myocardium were measured by immunohistochemical staining. In addition, the protein expressions of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2) were detected by Western blot.
RESULTS: Compared to Group A, the cardiac function was obviously improved (P<0.05) and the plaque positive area (%) was significantly decreased in Group B (45.82 +/- 3.68 vs 82.56 +/- 4.97, P<0.01). The CD34 positive response intensity and the capillary density as well as VEGF and VEGFR-2 expressions in infarcted marginal zone in Group A were higher than those in Group B (P<0.01); but these parameters at aorta vessel walls were lower in Group A than in Group B (P<0.01).
CONCLUSION: SBP could advance the angiogenesis in the marginal zone of infarction, improve heart function, and embarrass angiogenesis in atherosclerotic plaque.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21302492

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  7 in total

1.  Shexiang Baoxin pills promotes angiogenesis in myocardial infarction rats via up-regulation of 20-HETE-mediated endothelial progenitor cells mobilization.

Authors:  Feifei Huang; Yang Liu; Xia Yang; Di Che; Kaifeng Qiu; Bruce D Hammock; Jingfeng Wang; Mong-Heng Wang; Jie Chen; Hui Huang
Journal:  Atherosclerosis       Date:  2017-06-07       Impact factor: 5.162

2.  A network-based method for mechanistic investigation of Shexiang Baoxin Pill's treatment of cardiovascular diseases.

Authors:  Hai-Yang Fang; Hua-Wu Zeng; Li-Mei Lin; Xing Chen; Xiao-Na Shen; Peng Fu; Chao Lv; Qun Liu; Run-Hui Liu; Wei-Dong Zhang; Jing Zhao
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379

Review 3.  Holistic Regulation of Angiogenesis with Chinese Herbal Medicines as a New Option for Coronary Artery Disease.

Authors:  Rong Yuan; Wei-Li Shi; Qi-Qi Xin; Ke-Ji Chen; Wei-Hong Cong
Journal:  Evid Based Complement Alternat Med       Date:  2018-08-13       Impact factor: 2.629

4.  Combination of Ginsenosides Rb2 and Rg3 Promotes Angiogenic Phenotype of Human Endothelial Cells via PI3K/Akt and MAPK/ERK Pathways.

Authors:  Ran Joo Choi; Siti Zuraidah Mohamad Zobir; Ben Alexander-Dann; Nitin Sharma; Marcella K L Ma; Brian Y H Lam; Giles S H Yeo; Weidong Zhang; Tai-Ping Fan; Andreas Bender
Journal:  Front Pharmacol       Date:  2021-02-10       Impact factor: 5.810

5.  Beneficial effects of muscone on cardiac remodeling in a mouse model of myocardial infarction.

Authors:  Xiaoyan Wang; Haoyu Meng; Pengsheng Chen; Naiquan Yang; Xin Lu; Ze-Mu Wang; Wei Gao; Ningtian Zhou; Min Zhang; Zhihui Xu; Bo Chen; Zhengxian Tao; Liangsheng Wang; Zhijian Yang; Tiebin Zhu
Journal:  Int J Mol Med       Date:  2014-05-02       Impact factor: 4.101

Review 6.  Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review.

Authors:  Dongqing Guo; Colin E Murdoch; Tianhua Liu; Jia Qu; Shihong Jiao; Yong Wang; Wei Wang; Xing Chen
Journal:  Front Pharmacol       Date:  2018-04-26       Impact factor: 5.810

Review 7.  Shexiang Baoxin Pill, Derived From the Traditional Chinese Medicine, Provides Protective Roles Against Cardiovascular Diseases.

Authors:  Li Lu; Xiaodong Sun; Chen Chen; Yating Qin; Xiaomei Guo
Journal:  Front Pharmacol       Date:  2018-11-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.